Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$0.16 - $1.64 $252,250 - $2.59 Million
1,576,565 Added 30.51%
6,744,585 $1.21 Million
Q2 2023

Aug 11, 2023

BUY
$0.66 - $1.22 $66,000 - $122,000
100,000 Added 1.97%
5,168,020 $6.2 Million
Q1 2023

May 12, 2023

BUY
$0.59 - $1.04 $93,984 - $165,666
159,295 Added 3.25%
5,068,020 $3.5 Million
Q2 2022

Aug 12, 2022

SELL
$0.51 - $0.93 $12,392 - $22,598
-24,299 Reduced 0.49%
4,908,725 $3.34 Million
Q1 2022

May 13, 2022

BUY
$0.84 - $1.71 $2.09 Million - $4.25 Million
2,483,757 Added 101.41%
4,933,024 $4.13 Million
Q4 2021

Feb 11, 2022

BUY
$1.59 - $2.38 $937,514 - $1.4 Million
589,632 Added 31.71%
2,449,267 $3.99 Million
Q3 2021

Nov 12, 2021

BUY
$1.69 - $2.89 $197,491 - $337,722
116,859 Added 6.71%
1,859,635 $4.48 Million
Q2 2021

Aug 13, 2021

BUY
$2.64 - $6.32 $1.37 Million - $3.27 Million
517,532 Added 42.24%
1,742,776 $4.6 Million
Q1 2021

May 14, 2021

BUY
$1.35 - $4.99 $1.65 Million - $6.11 Million
1,225,244 New
1,225,244 $6.11 Million

Others Institutions Holding SEEL

# of Institutions
1
Shares Held
40.5K
Call Options Held
0
Put Options Held
0

About SEELOS THERAPEUTICS, INC.


  • Ticker SEEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 106,691,000
  • Market Cap $59.7M
  • Description
  • Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...
More about SEEL
Track This Portfolio

Track Gendell Jeffrey L Portfolio

Follow Gendell Jeffrey L and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gendell Jeffrey L, based on Form 13F filings with the SEC.

News

Stay updated on Gendell Jeffrey L with notifications on news.